new Treatment Strategies Researchers tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment.
This approach also helps to slow down the need for hormone therapy.
Findings presented at the annual American Society of Radiation Oncology (Astro) conference this week showed that they combined targets. Radioactive drugs Standard radiotherapy has more than doubled the time patients remained free of disease progression.
New breast cancer drugs win FDA approval after reducing progression risk by nearly 40%
the study Focusing on men In the form of cancer recurrence, where the disease had returned with only a few isolated spots. Traditionally, this has been treated with a type of intensive radiation called stereoscopic radiotherapy, which is a very accurate type of radiation therapy used to treat tumors in the body.
According to a press release, the UCLA-led team wanted to determine whether to add PSMA-targeted radioradiotherapy, a radioactive drug that will become zero-caused in cancer cells.
The researchers enrolled 92 men with prostate cancer in the trial. Half of them received only radiation, while the other half received new medicines and radiation.
Men who received both treatments remained No cancer Median for about 18 months compared to about 7 months for those who acquired radiation alone.
Click here to sign up for our health newsletter
“This is the first Randomized trials To demonstrate that PSMA targeting radioligands can significantly slow progression when added to metastasis-directed radiation,” Dr. Amar Kishan, executive vice chair for radiation oncology at UCLA and lead author of the study, told Fox News Digital.
Kishan called the work “a wonderful example of the true collaboration between radiation oncology and nuclear medicine.”
According to Kishan, one of the biggest advantages is the possibility that patients may delay the onset of hormone therapy. This is a common next step, but often it can be fatigue, bone loss, Changes in mood.
“We give patients more time before they need hormone therapy,” Kishan said. “Evasion or delaying hormone therapy is consistently helpful for quality of life.”
Despite improvements, cancer has ultimately returned for many patients.
“There’s always room for improvement,” Kishan pointed out. “There were still events going on… Optimize treatment Even further away. “
A new drug called 177LU-PNT2002 has not yet been approved by the FDA for use at this stage of the disease.
For now, Kishan is a man experiencing their spread. Prostate cancer Areas other than the prostate should be “explored options for consultation with a radiation oncologist.”
